Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole for agitation in Alzheimer's dementia
2013-000503-17Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Brexpiprazole flexible dose with Placebo (2 arms). Primary endpoint: Change from baseline to Week 12/early termination in CMAI total score. Started Mar 2014; status: completed.
02
Drugs
brexpiprazole
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2013-000503-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000503-17.